| chronic pain (diagnosis)
Mitigo vs Butrans
Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).Deep comparison between: Mitigo vs Butrans with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsButrans has a higher rate of injection site reactions vs Mitigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Butrans but not Mitigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mitigo
Butrans
At A Glance
Epidural/intrathecal infusion
Daily (continuous infusion)
Opioid agonist
Transdermal patch
Every 7 days
Partial mu-opioid agonist
Indications
- chronic pain (diagnosis)
- chronic pain (diagnosis)
Dosing
chronic pain (diagnosis) - Epidural Initial 3.5-7.5 mg/day (opioid-naive) or 4.5-10 mg/day (opioid-tolerant) via continuous epidural infusion; dose requirements may increase to 20-30 mg/day; titrate individually to adequate analgesia.
chronic pain (diagnosis) - Intrathecal Initial 0.2-1 mg/day (opioid-naive) or 1-10 mg/day (opioid-tolerant) via lumbar intrathecal infusion; intrathecal dose is typically 1/10 of epidural dose; doses above 20 mg/day should be used with caution.
chronic pain (diagnosis) For opioid-naive patients, initiate with BUTRANS 5 mcg/hour transdermal patch worn for 7 days; for patients on 30-80 mg/day oral morphine equivalents, taper current opioid to <=30 mg/day then initiate at 10 mcg/hour; maximum dose is 20 mcg/hour (one system); titrate no more frequently than every 72 hours in increments of 5, 7.5, or 10 mcg/hour.
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
- Concurrent use of MAOIs or use within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
- Infection at the neuraxial injection or microinfusion site
- Concomitant anticoagulant therapy (neuraxial administration)
- Uncontrolled bleeding diathesis (neuraxial administration)
- Any concomitant therapy or medical condition rendering epidural or intrathecal administration especially hazardous
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity (e.g., anaphylaxis) to buprenorphine or any excipient
Adverse Reactions
Most common Nausea, vomiting, constipation, pruritus, urinary retention, dizziness, headache, myoclonus, anxiety, confusion
Serious Respiratory depression, myoclonus, inflammatory masses, seizures, severe hypotension, adrenal insufficiency, serotonin syndrome, anaphylaxis
Postmarketing Androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Most common (>=5%) Nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, application site rash
Serious Life-threatening respiratory depression, addiction/abuse/misuse, interactions with CNS depressants, neonatal opioid withdrawal syndrome, QTc prolongation, anaphylaxis/allergic reactions, hepatotoxicity, seizures, adrenal insufficiency, severe hypotension
Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, hypoglycemia, opioid-induced esophageal dysfunction
Pharmacology
Morphine is a full opioid agonist selective for the mu-opioid receptor that produces analgesia through CNS opioid receptors in the brain and spinal cord; it also causes respiratory depression by direct action on brain stem respiratory centers and reduces GI motility through smooth muscle effects.
Buprenorphine is a partial agonist at the mu-opioid receptor, an antagonist at kappa-opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors; it produces analgesia and respiratory depression via central opioid receptor modulation, with pharmacodynamic effects including CNS depression, reduced GI motility, and peripheral vasodilation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mitigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
Butrans
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Mitigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Butrans
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Mitigo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Butrans
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Mitigo.
No savings programs available for Butrans.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MitigoView full Mitigo profile
ButransView full Butrans profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.